HER-2与TMEM106B在脑膜瘤细胞增殖和血管生成过程中的表达及意义

发布时间：2019-04-27 10:38

【摘要】：目的:检测脑膜瘤组织中的TMEM106B、HER-2、VEGF和CD34蛋白的表达情况,探讨HER-2和TMEM106B蛋白与脑膜瘤细胞的增殖和血管生成的关系,以期进一步了解脑膜瘤的发生、进展的机制,可能为后续脑膜瘤的靶向治疗提供实验数据。方法:选取2007年1月1日-2015年12月31日南昌大学第一附属医院病理科脑膜瘤患者术后石蜡标本50例,以及20例正常脑膜石蜡标本作为对照,对照组脑膜组织均取自颅脑损伤后接受颅内血肿清除术+去骨瓣减压的患者。采用Max VisionTM免疫组化法分别检测两组样本中TMEM106B、HER-2、VEGF和CD34蛋白的表达情况,并采用UTHSCSA Image Tool图文分析软件计算微血管密度(MVD)。结果:1.HER-2在本组脑膜瘤组织中有较高的阳性检出率36%(18/50),但在正常脑膜组织中HER-2的表达均为阴性,两者的表达差异具有统计学意义(X2=9.692,P0.05)。但对HER-2的进一步研究表明HER-2的阳性率并没有随着脑膜瘤组织的恶性程度的升高而升高,WHOI级脑膜瘤组织的HER-2阳性率为:28.6%(6/21),WHOII级脑膜瘤组织的HER-2阳性率为:44.4%(8/18),WHOIII级脑膜瘤组织的阳性率为:36.4%(4/11),其差异性没有统计学意义(X2=2.007,P0.05)。2.TMEM106B在脑膜瘤组织中阳性检出率82%(41/50),但在正常脑膜组织中TMEM106B的表达均为阴性,两者表达差异有统计学意义(X2=39.586P0.05)。对TMEM106B的研究结果表明TMEM106B的阳性率未表现为随着脑膜瘤组织的恶性程度的升高而升高情况,WHOI级脑膜瘤组织的TMEM106B阳性率为81%(17/21),WHOII级脑膜瘤组织的TMEM106B阳性率为77.8%(14/18),WHOIII级脑膜瘤组织的阳性率为90.9%(10/11),表达差异无统计学意义(X2=0.004,P0.05)。3.MVD和VEGF在正常脑膜瘤组织均为阴性,而在脑膜瘤组织中表达率显著提高(18.04±19.85)和70%(35/50),差异均有统计学意义(X2=9.692,P0.05;T=9.427,P0.05),不同级别脑膜瘤中:WHOI级脑膜瘤组织的CD34和VEGF为:(5.77±10.18)和66.7%(14/21),WHOII、III级脑膜瘤组织中的CD34和VEGF阳性率为:(26.92±20.53)和72.41%(21/29),差异有统计学意义(P0.05)。4.经Spearman秩相关分析,HER-2与VEGF、MVD均呈正相关。HER-2与VEGF呈正相关(r=0.113 P0.05),与MVD呈正相关(r=0.058,P0.05);TMEM106B与VEGF呈正相关(r=0.293 P0.05)、与MVD呈正相关(r=0.146P0.05);VEGF与MVD呈正相关(P0.05,r=0.170)。HER-2与TMEM106B呈正相关(P0.05,r=0.115)。结论:1.HER-2和TMEM106B在脑膜瘤细胞中均存在过表达,但其阳性表达率与脑膜瘤的恶性程度无统计学意义,HER-2和TMEM106B均参与了脑膜瘤细胞的增殖和血管的生成。2.HER-2可能通过调节TMEM106B来影响脑膜细胞的增殖和血管生成。
[Abstract]:Objective: to detect the expression of TMEM106B,HER-2,VEGF and CD34 proteins in meningiomas and to explore the relationship between HER-2 and TMEM106B proteins and the proliferation and angiogenesis of meningioma cells, so as to further understand the pathogenesis and progression of meningiomas, and to explore the relationship between the expression of HER-2 and TMEM106B proteins and the proliferation and angiogenesis of meningioma cells. Experimental data may be provided for targeted therapy for subsequent meningiomas. Methods: from January 1, 2007 to December 31, 2015, paraffin-embedded specimens were collected from 50 patients with meningiomas and 20 normal meningeal specimens from pathology department of the first affiliated Hospital of Nanchang University as control. The meningeal tissue of the control group was removed from the craniocerebral injury patients who received craniocerebral hematoma debridement with bone flap decompression. The expression of TMEM106B,HER-2,VEGF and CD34 proteins in two groups of samples were detected by Max VisionTM immunohistochemical method, and the microvessel density (MVD).) was calculated by UTHSCSA Image Tool graphic and textual analysis software. Results: the positive rate of 1.HER-2 in meningiomas was 36% (18 / 50), but the expression of HER-2 was negative in normal meningeal tissues. (P0.05). However, further study of HER-2 showed that the positive rate of HER-2 did not increase with the malignant degree of meningiomas. The positive rate of HER-2 in WHOI grade meningiomas was 28.6% (6 / 21), and the positive rate of HER-2 in meningiomas of grade WHOI was 28.6% (6 / 21). The positive rate of HER-2 in meningiomas of WHOII grade was 44.4% (8 / 18), WHOIII), which was 36.4% (4 / 11), and there was no significant difference between them (X2 / 2.007, P < 0.01). 2. The positive rate of TMEM106B in meningiomas was 82% (41? 50), but the expression of TMEM106B in normal meningeal tissues was negative. There was significant difference (X2=39.586P0.05) between TMEM106B and TMEM106B. The results of TMEM106B showed that the positive rate of TMEM106B did not increase with the malignant degree of meningiomas. The positive rate of TMEM106B in WHOI grade meningiomas was 81% (17 / 21). The positive rate of TMEM106B in WHOII grade meningiomas was 77.8% (14 / 18), WHOIII grade meningiomas was 90.9% (10 / 11), and there was no significant difference in the expression rate (X 2, 0.004, P < 0.01). (P0.05) .3.MVD and VEGF were negative in normal meningiomas, but increased significantly in meningiomas (18.04 卤19.85) and 70% (35 渭 50), the difference was statistically significant (X _ 2, 9.692, P 0.05), while the expression rates of MVD and MVD in meningiomas were significantly higher than those in normal meningiomas (18.04 卤19.85) and 70% (35 卤50), respectively. CD34 and VEGF were (5.77 卤10.18) and 66.7% (14 / 21), WHOII,) in different grades of meningiomas: WHOI meningiomas: (5.77 卤10.18) and 66.7% (P < 0.05). The positive rates of CD34 and VEGF in III grade meningiomas were (26.92 卤20.53) and 72.41% (21 / 29), the difference was statistically significant (P0.05). Spearman rank correlation analysis showed that HER-2 was positively correlated with VEGF,MVD, her-2 was positively correlated with VEGF (r = 0.113, P0.05), and was positively correlated with MVD (r = 0.058, P0.05). There was a positive correlation between TMEM106B and VEGF (r = 0.293 P0.05), a positive correlation between r=0.146P0.05); VEGF and MVD (P 0.05, r = 0.170) and a positive correlation between HER-2 and TMEM106B (P 0.05, r = 0.115). Conclusion: both 1.HER-2 and TMEM106B are overexpressed in meningioma cells, but there is no significant difference between the positive expression rate and the malignant degree of meningioma. Both HER-2 and TMEM106B are involved in the proliferation and angiogenesis of meningioma cells. 2. Her-2 may influence the proliferation and angiogenesis of meningeal cells by regulating TMEM106B.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R739.45

【参考文献】